This study is in progress, not accepting new patients
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Summary
- Eligibility
- for people ages up to 21 years (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors Sign up for this study
- ID
- NCT04238819
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 117 study participants
- Last Updated